Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19
Background: Many treatments are being assessed for repurposing to treat coronavirus disease 2019 (COVID-19). One drug that has shown promising results in vitro is nitazoxanide. Unlike other postulated drugs, nitazoxanide shows a high ratio of maximum plasma concentration (Cmax), after 1 day of 500 m...
Saved in:
Main Authors: | Toby Pepperrell (Author), Victoria Pilkington (Author), Andrew Owen (Author), Junzheng Wang (Author), Andrew M. Hill (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
by: Victoria Pilkington, et al.
Published: (2020) -
Minimum costs to manufacture new treatments for COVID-19
by: Andrew Hill, et al.
Published: (2020) -
Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future
by: Victoria Pilkington, et al.
Published: (2022) -
Efficacy and safety of nitazoxanide, albendazole, and nitazoxanide-albendazole against Trichuris trichiura infection: a randomized controlled trial.
by: Benjamin Speich, et al.
Published: (2012) -
Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
by: Andrew Hill, et al.
Published: (2015)